Bausch + Lomb (BLCO) said Thursday it is voluntarily recalling the intraocular lenses on its enVista platform after reports of complications.
The company said it received an increased number of reports of toxic anterior segment syndrome related to its enVista Aspire, enVista Envy, and certain enVista monofocal intraocular lenses. The syndrome is an inflammatory reaction inside the eye typically caused by the introduction of toxic substances into the eye.
The company said that the cause of the incidents "could not immediately be explained."
"These reports represent an extremely small percentage of implanted lenses, with a positive prognosis for everyone involved," said Brent Saunders, chairman and CEO of Bausch + Lomb. "We look forward to identifying a root cause and bringing the enVista platform back to market."
Bausch + Lomb shares were down by more than 4% in premarket trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.